First Long Island Investors LLC lowered its holdings in Amgen, Inc. (NASDAQ:AMGN) by 0.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 106,506 shares of the medical research company’s stock after selling 712 shares during the quarter. Amgen accounts for 2.5% of First Long Island Investors LLC’s holdings, making the stock its 11th biggest position. First Long Island Investors LLC’s holdings in Amgen were worth $20,610,000 as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in the company. Advisors Preferred LLC purchased a new position in shares of Amgen during the 2nd quarter worth about $30,000. Arbor Wealth Management LLC grew its position in Amgen by 154.5% in the second quarter. Arbor Wealth Management LLC now owns 168 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 102 shares in the last quarter. Atwater Malick LLC acquired a new stake in Amgen in the third quarter valued at approximately $39,000. Ashburton Jersey Ltd purchased a new position in shares of Amgen during the 2nd quarter valued at approximately $42,000. Finally, Sound Income Strategies LLC boosted its stake in shares of Amgen by 402.1% during the 2nd quarter. Sound Income Strategies LLC now owns 236 shares of the medical research company’s stock valued at $43,000 after buying an additional 189 shares during the last quarter. Hedge funds and other institutional investors own 77.06% of the company’s stock.
Amgen stock opened at $220.70 on Tuesday. The stock’s fifty day moving average price is $203.70 and its two-hundred day moving average price is $189.34. Amgen, Inc. has a one year low of $166.30 and a one year high of $221.38. The company has a debt-to-equity ratio of 2.54, a current ratio of 2.89 and a quick ratio of 2.59. The firm has a market cap of $131.38 billion, a PE ratio of 15.33, a price-to-earnings-growth ratio of 2.27 and a beta of 1.09.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 6th. Shareholders of record on Friday, November 15th will be paid a dividend of $1.45 per share. The ex-dividend date of this dividend is Thursday, November 14th. This represents a $5.80 dividend on an annualized basis and a yield of 2.63%. Amgen’s dividend payout ratio (DPR) is presently 40.28%.
In other news, SVP Cynthia M. Patton sold 13,426 shares of Amgen stock in a transaction on Friday, August 30th. The stock was sold at an average price of $208.07, for a total value of $2,793,547.82. Following the transaction, the senior vice president now owns 32,648 shares in the company, valued at approximately $6,793,069.36. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director R Sanders Williams sold 425 shares of Amgen stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $215.45, for a total value of $91,566.25. Following the completion of the transaction, the director now owns 5,413 shares in the company, valued at approximately $1,166,230.85. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 17,851 shares of company stock worth $3,685,674. Corporate insiders own 0.25% of the company’s stock.
Several equities analysts recently issued reports on the company. Credit Suisse Group restated an “outperform” rating and set a $225.00 price objective (up from $202.00) on shares of Amgen in a research note on Friday, August 16th. Royal Bank of Canada reissued a “hold” rating on shares of Amgen in a report on Monday, September 30th. Goldman Sachs Group set a $243.00 target price on Amgen and gave the stock a “buy” rating in a report on Monday, September 30th. BMO Capital Markets set a $240.00 target price on Amgen and gave the stock a “buy” rating in a report on Monday, September 30th. Finally, JPMorgan Chase & Co. reissued a “hold” rating on shares of Amgen in a research note on Monday, September 30th. Ten analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $221.47.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Featured Story: What is the return on assets formula?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.